Table 3.

Antifungal Product Type in the Pipeline, Pathogen, Phase of Clinical Trial and Expected Activity Against Fusarium

Pathogen	Compound (Notes)	Company	Development Status	Antifungal Class	Activity (MIC μg/mL)	Related Ref.s
Fusarium	Isavuconazole	Astellas Pharma, US, Inc. – License holder Basilea Pharmaceu., Switzerland – outside USA and Canada	FDA approves new antifungal drug Cresemba (Oral/IV) March 6, 2015	Triazole	Variable from 1 to ≥16	70
	Efinaconazole (KP-103)	JUBLIA® Valeant Pharmaceu., Canada	FDA approval: September 2014 Topical 10%	Triazole	0.85	83
	Luliconazole (NND-502)	Nihon Nohyaku Co Ltd (Osaka, Japan)	Approved, USA, Nov 15, 2013 Cream 1%, solution 10%	Imidazole	0.005	83
	Lanoconazole	Nihon Nohyaku Co Ltd (Osaka, Japan)	Approved, USA, Nov 15, 2013 Cream 1%, solution 10%	Imidazole	0.013	83
	AR-12 celecoxib derivative	Arno Therapeutics, Flemington, NJ, USA)	-	Celecoxib Derivative	4	89
	F901318 = Olorofim	F2G, Manchester, UK	Phase 2 Preclinical	Orotomides	1 to 2	93
	E1210 Inositol acyltransferase inhibitor Oral	Eisai Co., Japan	Preclinical	-	−0.015–0.25 -0.12	94
	SCY078 (formerly MK-3118) IV/Oral	Scynexis, Durham, NC, USA	Phase 2	Triterpene/Enfumafungin derivative	poor activity	97
	T-2307 Arylamidine derivatives	Toyama, Japan	Preclinical	Arylamidine derivatives	0.125	99
MGCD290 Oral histone deacetylase inhibitor	Mirati Therapeu., CA, USA	Phase 2	Hos2 histone deacetylase inhibitor	Effective in combination	101